CD38-directed Cytolytic Antibody [EPC] - N0000192336

Pharmacologic Class Information

Pharmacologic Code N0000192336
Pharmacologic Name CD38-directed Cytolytic Antibody
Pharmacologic Uses
  • CD38-directed cytolytic antibody
Pharmacologic Concept Established Pharmacologic Classes - [EPC]
Pharmacologic Concept Description An established pharmacologic class is a term or phrase that is scientifically valid and clinically meaningful according to the following definitions:
  • A scientifically valid pharmacologic class is supported by documented and submitted empiric evidence showing that the drug's pharmacologic class is known, not theoretical, and relevant and specific to the indication.
  • A clinically meaningful pharmacologic class term or phrase enhances the ability of professionals to understand physiologic effects related to the indication or to anticipate undesirable effects that may be associated with the drug or pharmacologic class.

NDC Products with CD38-directed Cytolytic Antibody

The table contains 5 products whose active ingredient are classified under the same pharmacologic class CD38-directed Cytolytic Antibody [EPC].

NDC Proprietary Name Non-Proprietary Name Dosage Form Route Name Company Name Status
0024-0654Sarclisa Non-Proprietary Name: IsatuximabInjection, Solution, ConcentrateIntravenousSanof-aventis U.s. LlcACTIVE
0024-0656Sarclisa Non-Proprietary Name: IsatuximabInjection, Solution, ConcentrateIntravenousSanof-aventis U.s. LlcACTIVE
57894-502Darzalex Non-Proprietary Name: DaratumumabInjection, Solution, ConcentrateIntravenousJanssen Biotech, Inc.ACTIVE
57894-503Darzalex Faspro Non-Proprietary Name: Daratumumab And Hyaluronidase-fihj (human Recombinant)InjectionSubcutaneousJanssen Biotech, Inc.ACTIVE
57894-505Darzalex Iv Non-Proprietary Name: DaratumumabInjection, Solution, ConcentrateIntravenousJanssen Biotech, Inc.ACTIVE